Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma

This is a prospective, multicenter phase II clinical study. The subjects are patients with previously untreated locally advanced nasopharyngeal carcinoma, with clinical staging of IVA, T1-4, N3, M0. The study aims to preliminarily evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injectionin the treatment of these patients.

NCT Number	NCT07135804
Lead Sponsor	Second Affiliated Hospital of Nanchang University
Conditions	Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
Enrollment	45 participants
Start Date	2025-09-01
Primary Completion	2028-04-30 (estimated)
Study Completion	2031-04-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-22